RE:Sigilon The fact Siligon has Lilly and Black Rock backing them with $100 million financing and exercised all their options tells me Siligon is not far way from success. Any positive clinical development from Siligon will be very detrimental to Sva imo. They have the funds and management to succeed .
Unless management can get collaboration with pharma with money along with it , you can say that Sva is undervalued . But with current circumstances , the market is accurately valuing Sva at 30 cents and not at $2 . Now why is that ? Perhaps Management succeeds and everything goes well. But the market surely doesn't think so imo.
Its do or die for management especially since now Tolekis has put a line in the sand with 3 month expiry date with warrants. Poker game is it a full house or bluff.... the market tells the tale.
Elgin